title: Incidence of major clinical outcomes in a cohort of Ugandan and Zimbabwean women with HIV-1 infection followed from seroconversion.
abstract: We conducted a prospective cohort study of 306 HIV-1-infected women, followed from seroconversion for median 6.4 years in Uganda (UG) and Zimbabwe (ZM) to describe the incidence of major clinical outcomes (MCOs), defined as World Health Organization stage 4 conditions and any tuberculosis (TB). In Uganda, 19 MCOs occurred in 13 participants at median 4.6 years and a median CD4 count of 213 cells/mm(3). In Zimbabwe, 29 MCOs occurred in 27 participants at median 4.0 years (P < 0.001 versus UG) and median CD4 count of 219 cells/mm(3) (P = 0.83 versus UG). MCO incidence was not statistically different (UG: 2.82 cases/100 person-years versus ZM: 2.45; P = 0.64) except for TB (UG: 0.59 versus ZM: 2.02 cases/100 person-years; P = 0.02). This significant difference in TB incidence is primarily due to a TB screening and isoniazid prevention therapy programme that was implemented in Uganda, but not in Zimbabwe, highlighting the importance of integrated TB screening and treatment within HIV programmes.
authors.affiliation: Case Western Reserve University, Cleveland, OH 44106-5094, USA.
authors.forename: D
authors.initials: D
authors.lastname: Beversluis
authors.forename: R
authors.initials: R
authors.lastname: Musoke
authors.forename: P
authors.initials: P
authors.lastname: Mandima
authors.forename: P
authors.initials: P
authors.lastname: Nyamapfeni
authors.forename: T
authors.initials: T
authors.lastname: Chipato
authors.forename: J B
authors.initials: JB
authors.lastname: Mukasa
authors.forename: J
authors.initials: J
authors.lastname: Byamugisha
authors.forename: R
authors.initials: R
authors.lastname: Mugerwa
authors.forename: C
authors.initials: C
authors.lastname: Morrison
authors.forename: R A
authors.initials: RA
authors.lastname: Salata
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology / Q000473:pathology / Q000628:therapy; D000328:Adult; D005260:Female; D015658:HIV Infections / Q000382:microbiology / Q000473:pathology* / Q000628:therapy; D006679:HIV Seropositivity / Q000473:pathology* / Q000628:therapy; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D011446:Prospective Studies; D016896:Treatment Outcome; D014376:Tuberculosis / Q000473:pathology / Q000628:therapy / Q000821:virology; D014454:Uganda; D015030:Zimbabwe